[{"modalityCui": "SIO_001210", "suffix": "The clinical significance of these changes is unknown.", "drugOneName": "sertraline", "label": "11", "prefix": "", "drugTwoName": "cimetidine", "drugTwoCui": "http://purl.bioontology.org/ontology/RXNORM/2541", "exact": "In a study assessing disposition of sertraline (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline mean AUC (50%), C max (24%) and half-life (26%) compared to the placebo group. ", "modality": "positive", "drugOneCui": "http://purl.bioontology.org/ontology/MSH/D020280"}, {"modalityCui": "SIO_001210", "suffix": "The clinical significance of these changes is unknown.", "drugOneName": "desmethyldiazepam", "label": "12", "prefix": "", "drugTwoName": "sertraline", "drugTwoCui": "http://purl.bioontology.org/ontology/MSH/D020280", "exact": "In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p < 0.03). There was a 23% increase in T max for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p < 0.03). ", "modality": "positive", "drugOneCui": "http://purl.bioontology.org/ontology/MSH/D003708"}, {"modalityCui": "SIO_001210", "suffix": "There was a 23% increase in T max for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p < 0.03). The clinical significance of these changes is unknown.", "drugOneName": "diazepam", "label": "12", "prefix": "", "drugTwoName": "sertraline", "drugTwoCui": "http://purl.bioontology.org/ontology/MSH/D020280", "exact": "In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p < 0.03). ", "modality": "positive", "drugOneCui": "http://purl.bioontology.org/ontology/MSH/D003975"}, {"modalityCui": "SIO_001210", "suffix": "Since the highest recommended pimozide dose (10 mg) has not been evaluated in combination with sertraline, the effect on QT interval and PK parameters at doses higher than 2 mg at this time are not known. While the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide and due to the interaction noted at a low dose of pimozide, concomitant administration of sertraline and pimozide should be contraindicated (see CONTRAINDICATIONS).", "drugOneName": "sertraline", "label": "14", "prefix": "", "drugTwoName": "pimozide", "drugTwoCui": "http://purl.bioontology.org/ontology/RXNORM/8331", "exact": "In a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) co-adminis-tration to steady state was associated with a mean increase in pimozide AUC and C max of about 40%, but was not associated with any changes in EKG. ", "modality": "positive", "drugOneCui": "http://purl.bioontology.org/ontology/RXNORM/36437"}, {"modalityCui": "SIO_001211", "suffix": "Nonetheless, at this time, it is recommended that plasma phenytoin concentrations be monitored following initiation of sertraline therapy with appropriate adjustments to the phenytoin dose, particularly in patients with multiple underlying medical conditions and/or those receiving multiple concomitant medications.", "drugOneName": "phenytoin", "label": "15", "prefix": "", "drugTwoName": "sertraline", "drugTwoCui": "http://purl.bioontology.org/ontology/MSH/D020280", "exact": "Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism. ", "modality": "negative", "drugOneCui": "http://purl.bioontology.org/ontology/MSH/D010672"}, {"modalityCui": "SIO_001210", "suffix": "Sertraline administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabolism of the drug. The clinical significance of this decrease in tolbutamide clearance is unknown.", "drugOneName": "tolbutamide", "label": "17", "prefix": "", "drugTwoName": "sertraline", "drugTwoCui": "http://purl.bioontology.org/ontology/MSH/D020280", "exact": "In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose. ", "modality": "positive", "drugOneCui": "http://purl.bioontology.org/ontology/RXNORM/10635"}, {"modalityCui": "SIO_001211", "suffix": "", "drugOneName": "sertraline", "label": "18", "prefix": "", "drugTwoName": "atenolol", "drugTwoCui": "http://purl.bioontology.org/ontology/MSH/D001262", "exact": "Sertraline (100 mg) when administered to 10 healthy male subjects had no effect on the beta-adrenergic blocking ability of atenolol.", "modality": "negative", "drugOneCui": "http://purl.bioontology.org/ontology/RXNORM/10635"}, {"modalityCui": "SIO_001211", "suffix": "", "drugOneName": "sertraline", "label": "19", "prefix": "", "drugTwoName": "digoxin", "drugTwoCui": "http://purl.bioontology.org/ontology/RXNORM/3407", "exact": "In a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance.", "modality": "negative", "drugOneCui": "http://purl.bioontology.org/ontology/MSH/D020280"}]